StockData
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX) stock

RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)

Close on Nov 16, 2026Market cap $1.56BP/E –Yield –

Recursion Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Recursion Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$465.65M. For fiscal 2025 it was -$564.43M. The highest annual figure on record is -$59.95M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$564.43M–
FY2024Dec 31, 2024-$442.51M–
FY2023Dec 31, 2023-$325.66M–
FY2022Dec 31, 2022-$233.97M–
FY2021Dec 31, 2021-$174.37M–
FY2020Dec 31, 2020-$80.67M–
FY2019Dec 31, 2019-$59.95M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$116.80M–
Q1 FY2026Mar 31, 2026-$108.83M–
Q4 FY2025Dec 31, 2025-$88.86M–
Q3 FY2025Sep 30, 2025-$151.16M–
Q2 FY2025Jun 30, 2025-$152.38M–
Q1 FY2025Mar 31, 2025-$172.04M–
Q4 FY2024Dec 31, 2024-$170.82M–
Q3 FY2024Sep 30, 2024-$91.16M–
Q2 FY2024Jun 30, 2024-$91.58M–
Q1 FY2024Mar 31, 2024-$88.96M–
Q4 FY2023Dec 31, 2023-$91.38M–
Q3 FY2023Sep 30, 2023-$91.97M–
Q2 FY2023Jun 30, 2023-$76.17M–
Q1 FY2023Mar 31, 2023-$66.14M–
Q4 FY2022Dec 31, 2022-$57.77M–
Q3 FY2022Sep 30, 2022-$59.58M–
Q2 FY2022Jun 30, 2022-$63.41M–
Q1 FY2022Mar 31, 2022-$53.21M–
Q4 FY2021Dec 31, 2021-$62.72M–
Q3 FY2021Sep 30, 2021-$43.97M–
Q2 FY2021Jun 30, 2021-$38.60M–
Q1 FY2021Mar 31, 2021-$29.08M–
Q4 FY2020Dec 31, 2020-$24.46M–
Q3 FY2020Sep 30, 2020-$21.62M–
Q2 FY2020Jun 30, 2020-$17.19M–
Q1 FY2020Mar 31, 2020-$17.41M–

More Recursion Pharmaceuticals figures

See a number that looks wrong?